Market revenue in 2023 | USD 8,736.6 million |
Market revenue in 2030 | USD 14,086.5 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Synthetic |
Fastest growing segment | Biotech |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Synthetic, Biotech |
Key market players worldwide | Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, AbbVie Inc, Aurobindo Pharma, Sandoz Group AG Registered Shares, Viatris Inc, Fresenius Kabi |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredients market will help companies and investors design strategic landscapes.
Synthetic was the largest segment with a revenue share of 69.6% in 2023. Horizon Databook has segmented the Japan active pharmaceutical ingredients market based on synthetic, biotech covering the revenue growth of each sub-segment from 2018 to 2030.
Changing market dynamics minimize opportunities for new companies. For instance, in January 2020, Sandoz announced completion of Aspen’s API business in Japan, which helped Sandoz strengthen its position in the world’s third largest market for off-patent and generic medicines. This portfolio expansion allowed Sandoz to cater to the generics market.
As Japan imports 50% of its API, companies tend to form partnerships with Japanese firms to enter the market to supply APIs. For instance, in February 2020, Astellas Pharma invested USD 90.8 million for expanding its API manufacturing facility in Toyama, Japan.
Moreover, in March 2022, Sumitomo Chemical Co., Ltd. established a new manufacturing plant in Oita, Japan for API, and intermediates for small molecule drugs. Thus, growing interest of global companies in Japan is expected to drive the market over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan active pharmaceutical ingredients market , including forecasts for subscribers. This country databook contains high-level insights into Japan active pharmaceutical ingredients market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account